Virtu Financial LLC Purchases 9,551 Shares of Rezolute, Inc. (NASDAQ:RZLT)

Virtu Financial LLC lifted its position in shares of Rezolute, Inc. (NASDAQ:RZLT) by 58.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,026 shares of the company’s stock after purchasing an additional 9,551 shares during the period. Virtu Financial LLC’s holdings in Rezolute were worth $126,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Federated Hermes Inc. boosted its position in Rezolute by 11.1% during the second quarter. Federated Hermes Inc. now owns 11,279,327 shares of the company’s stock worth $48,501,000 after purchasing an additional 1,125,000 shares during the period. Marshall Wace LLP bought a new stake in shares of Rezolute during the 2nd quarter worth about $4,503,000. Affinity Asset Advisors LLC boosted its holdings in shares of Rezolute by 15.6% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,850,000 shares of the company’s stock worth $7,955,000 after buying an additional 250,000 shares during the period. Geode Capital Management LLC grew its stake in Rezolute by 39.0% in the 3rd quarter. Geode Capital Management LLC now owns 491,601 shares of the company’s stock valued at $2,385,000 after buying an additional 137,905 shares during the last quarter. Finally, Acadian Asset Management LLC raised its holdings in Rezolute by 104.2% in the 2nd quarter. Acadian Asset Management LLC now owns 184,502 shares of the company’s stock valued at $792,000 after acquiring an additional 94,156 shares during the period. 82.97% of the stock is owned by institutional investors.

Insider Buying and Selling at Rezolute

In other Rezolute news, CFO Daron Evans acquired 10,000 shares of Rezolute stock in a transaction that occurred on Wednesday, December 18th. The shares were acquired at an average cost of $4.29 per share, with a total value of $42,900.00. Following the completion of the purchase, the chief financial officer now directly owns 150,900 shares of the company’s stock, valued at $647,361. This represents a 7.10 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders bought a total of 23,259 shares of company stock worth $104,317 over the last three months. Corporate insiders own 18.39% of the company’s stock.

Rezolute Stock Up 3.7 %

RZLT stock opened at $4.23 on Friday. The company has a market cap of $245.10 million, a PE ratio of -3.33 and a beta of 1.01. Rezolute, Inc. has a 52 week low of $0.86 and a 52 week high of $6.19. The business has a 50-day simple moving average of $5.13 and a 200 day simple moving average of $4.78.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings results on Thursday, September 19th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14). On average, analysts anticipate that Rezolute, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on RZLT shares. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Rezolute in a report on Friday, November 8th. BTIG Research upped their price objective on Rezolute from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, September 10th. Wedbush reiterated an “outperform” rating and set a $112.00 price objective on shares of Rezolute in a research report on Monday, November 4th. Guggenheim assumed coverage on shares of Rezolute in a research report on Tuesday, August 27th. They issued a “buy” rating and a $11.00 target price for the company. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $7.00 price target on shares of Rezolute in a research report on Friday, September 20th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $24.13.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.